HER2-Positive Breast Cancer Treatments
- Tucatinib (Tukysa®) combined with Trastuzumab (Herceptin®) and Capecitabine (Xeloda®): Proven to improve outcomes and control CNS disease in HER2-positive patients with brain metastases.
- Trastuzumab Deruxtecan (Enhertu®): An antibody-drug conjugate showing strong CNS activity and extended progression-free survival in ongoing studies.
Triple-Negative Breast Cancer (TNBC) Treatments
- Sacituzumab Govitecan (Trodelvy®): FDA-approved antibody-drug conjugate with promising results in patients with metastatic TNBC, including those with brain metastases.
- Pembrolizumab (Keytruda®) and other PD-1/PD-L1 checkpoint inhibitors: Being explored in combination regimens for TNBC with CNS involvement.
HR-Positive / HER2-Negative Breast Cancer Treatments
- Abemaciclib (Verzenio®): A CDK4/6 inhibitor that may offer benefit for patients with hormone receptor-positive breast cancer and brain metastases.
- Alpelisib (Piqray®) and other PI3K inhibitors: Under clinical investigation for treating CNS progression in hormone-positive disease.
This is a rapidly evolving space. Ask your oncologist about clinical trials or newly approved therapies that may address brain metastases based on your breast cancer subtype.
